drugset
drugset / Trial / NCT06157827

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

NCT06157827 ↗

Phase 1/2 Recruiting 178 enrolled Nanjing Leads Biolabs Co.,Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)

Timeline

Start
2023-12-08
Primary completion
2026-12-28
Completion
2027-03-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atezolizumab Monoclonal antibody — Intravenous
Subject LBL-024 Unknown — Intravenous
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified — Intravenous
Background Etoposide Small molecule — Intravenous

Indications

neuroendocrine carcinoma